Who are Ohtuvayre's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pletal, Primacor, Primacor, Anagrelide retard, intravenous milrinone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ensifentrine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ohtuvayre — Competitive Intelligence Brief

Ohtuvayre (ENSIFENTRINE) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase 3 Inhibitor [EPC]. Area: Respiratory.

marketed Phosphodiesterase 3 Inhibitor [EPC] Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Ohtuvayre (ENSIFENTRINE) — Verona Pharma. Ohtuvayre works by blocking an enzyme called phosphodiesterase 3, which helps to increase the levels of a molecule called cyclic AMP in the lungs.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ohtuvayre TARGET	ENSIFENTRINE	Verona Pharma	marketed	Phosphodiesterase 3 Inhibitor [EPC]		2024-01-01
Pletal	CILOSTAZOL	Otsuka	marketed	Phosphodiesterase 3 Inhibitor [EPC]	cGMP-inhibited 3',5'-cyclic phosphodiesterase A	1999-01-01
Primacor	Milrinone Lactate	Sanofi	marketed	Phosphodiesterase 3 Inhibitor	Phosphodiesterase 3	1987-01-01
Primacor	MILRINONE	Sanofi	marketed	Phosphodiesterase 3 Inhibitor	Phosphodiesterase 3	1987-01-01
Anagrelide retard	Anagrelide retard	AOP Orphan Pharmaceuticals AG	phase 3	Phosphodiesterase 3 inhibitor	Phosphodiesterase 3 (PDE3)
intravenous milrinone	intravenous milrinone	Konkuk University Medical Center	phase 3	Phosphodiesterase 3 inhibitor	Phosphodiesterase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase 3 Inhibitor [EPC] class)

Otsuka · 1 drug in this class
Verona Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ohtuvayre — Competitive Intelligence Brief. https://druglandscape.com/ci/ensifentrine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab